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ALTERNATING REGIMEN HYPER CVAD + IMATINIB IN PH (+) ALL PA-
TIENT ON HIGH-FLUX DIALYSIS
Stelts, S.D.1, Butler, C.2, Goorha, S.2 1Methodist University Hospital,
Memphis, TN; 2University of Tennessee Cancer Institute, Memphis, TN
Lack of pharmacokinetic data on chemotherapy clearance in
high flux hemodialysis hinders safe and effective dosing. We pres-
ent a case of a 58 year old female diagnosed in September 2009
with Ph (+) ALL and a past medical history of focal segmental glo-
merular sclerosis on hemodialysis. The patient intially presented
with worsening renal function, fevers and peripheral blasts.
Upon diagnosis of Ph (+) ALL, the decision was made to treat
with Hyper CVAD, a regimen of hyper fractionated cyclophos-
phamide, doxorubicin, vincristine and dexamethasone (odd cycle)
alternating cycles with high dose methotrexate and high dose
cytarabine (even cycle). High flux hemodialysis is relatively new,
utilizing improved membranes that efficiently remove low molec-
ular weight solutes and that are more effective at removing
medium and high molecular weight solutes. Currently the dosing
recommendations for chemotherapy are based on low flux hemo-
dialysis. Weighing the potential for improved solute clearance and
manufacturer dosing recommendations, no dose adjustments were
made for the odd cycles of Hyper CVAD. Imatinib was started at
100 mg for cycle 1, titrated up to 200 mg by cycle 3 and increased
to 400 mg at completion without side effects. Methotrexate is
poorly removed by low flux hemodialysis and only one case report
in a single patient provides pharmacokinetic information on
removal by high flux hemodialysis. For even cycles of Hyper
CVAD the methotrexate was initially dosed at 200 mg/m2, deter-
mined by estimating a dose cleared by 1 high flux hemodialysis
session using the time averaged clearance reported in the case
report by Murashima and colleagues. The methotrexate was
adequately removed based on serum levels and patient tolerance.
The dosage was increased to 500 mg/m2 for subsequent cycles.
Further dose escalation was halted due to development of febrile
neutropenia requiring hospitalization. Cytarabine was dosed at
100 mg/m2 continuous infusion for cycle 1 and increased to 200
mg/m2 base on manufacturer recommendations. The patient tol-
erated 8 cycles of Hyper CVAD with minimal side effects and 2
admissions for neutropenic fever. Complete remission was docu-
mented in December 2009. She remained in remission for 4
months after completion in April 2009. Recently reinduced with
Hyper CVAD, peg asparaginase, and dasatinib with documented
molecular remission.555
DRUG-DRUG INTERACTION BETWEEN TACROLIMUS AND AZOLE ANTI-
FUNGAL AGENTS, ITRACONAZOLE AND VORICONAZOLE, IN ALLOGENEIC
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Background: The blood concentration of tacrolimus (TAC) is
known to be increased by concomitant administration of voricona-
zole (VRCZ) and itraconazole (ITCZ), azole anti-fungal agents.
We investigated changes in blood concentrations of TAC before
and after concomitant administration of VRCZ or ITCZ to exam-
ine the optimal timing for monitoring blood concentrations of
TAC.
Patients and Methods: We studied retrospectively patients who
underwent hematopoietic stem cell transplantation between April
2004 and June 2010 and started VRCZ or ITCZ use during TAC
administration. In a total of 34 patients receiving concomitant ad-
ministration of VRCZ (tablets, n 5 27; intravenous injection, n 5
7) and 11 receiving ITCZ (capsules [Cap], n 5 8; oral solution
[OS], n 5 3), the concentration/dose (C/D) ratio of TAC was ob-served from 10 days before through 35 days after the initiation of
VRCZ or ITCZ.
Results: In all VRCZ group patients, C/D ratios of TAC in-
creased after initiating VRCZ as compared with those before
(median, 293%; range, 131%-923%; P \ 0.001). Median time
to reach the peak C/D ratio was 8 days (range, 3-30 days).
When a loading dose was applied, the peak reached earlier (me-
dian, 6 days vs. 9.5 days; P 5 0.026). Then C/D ratios decreased
from peak (median, 50%; range, 23%-98%; P\ 0.001). In 10 pa-
tients in the ITCZ group, the C/D ratio increased after initiating
ITCZ as compared with those before (median, 267%; range,
141%-828%; P \ 0.001). Median time to reach the peak C/D
ratio was 19.5 days (range, 10-32 days). Patient who applied
a loading dose was none. The rates of C/D ratio increase differed
significantly between Cap and OS (median, 221% [range, 38%-
475%] vs. 513% [range, 440%-828%]; P 5 0.025) and times to
reach the peak C/D ratio were similar (median, 20 days vs. 19
days).
Conclusions: In the VRCZ group, since blood concentrations of
TAC transiently increased and then decreased, suggesting that care-
ful monitoring is required even after dose reduction. It is also sug-
gested that the optimal times for careful monitoring differ
depending on whether or not the loading dose is applied. In the
ITCZ group, the effects tended to appear after about 1 week. Signif-
icant increases in blood concentrations of TAC were observed in
patients who received ITCZ by OS.556
CORRELATION OF PATIENT CHARACTERISTICS INCLUDING AGE, OBE-
SITY, GENDER AND RACE ON THE METABOLISM OF BUSULFAN
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Background: Busulfan, in myeloablative doses, is commonly used in
conditioning regimens prior to hematopoietic stem cell transplanta-
tion (HSCT) and is associated with HSCT related toxicity including
hepatic veno-occlusive disease (VOD). Busulfan is predominantly
metabolized by conjugation with glutathione, both spontaneously
and by glutathione S-transferase catalysis. Busulfan dosing is com-
monly adjusted using therapeutic drug monitoring (TDM) to limit
toxicities. Whether patient characteristics such as race, age, obesity,
gender and prior chemotherapy can influence the metabolism of bu-
sulfan remains unclear.
Methods: A retrospective chart review was conducted in 302 pa-
tients receiving intravenous busulfan between April 26th, 2001 and
September 23rd, 2010. Data was obtained from an IRB approved bu-
sulfanTDMdatabase and included gender, race, age, weight, height,
BSA, BMI and elimination half-life obtained with the 1st dose of bu-
sulfan.
Results: Demographics included 172 males and 130 females, of
which there were 222 Caucasians, 50 African Americans and 30 pa-
tients of other races. The mean age was 43 with 113 patients
greater than 50 years old. Thirty patients weighed over 100 kg, 6
had a BMI \ 18.5, 175 had a BMI of 18.5 – 29.9 and 122 had
a BMI . / 5 30. The mean half-life for all patients was 188 min-
utes (ranging 108 to 640 minutes). For the 12 patients with a BSA
of 2.5 to 3.29, the mean half-life was 206 minutes (ranging 184 to
238 minutes). The half-lives for the small to large BMI groups were
186, 188 and 186 minutes. The half-life for females was 180 min-
utes vs. 194 minutes for males. The half-lives for Caucasians, Afri-
can Americans and other races were 187, 194 and 182 minutes,
respectively. Patients over 50 years old had a mean half-life of
189 minutes. For the entire group, wide variations in clearance
were observed with 11% of patients having a half-life . 230 and
8%\ 145 minutes. The maximum and minimum half-lives were
640 and 108 minutes.
Conclusion: Initial analysis of our data suggests that different dos-
ing strategies based on population specific parameters may not be
necessary. Pharmacists should continue to dose busulfan according
to their institutional guidelines but due to the wide variations
